One fail and one success, should it be accepted? [Regulatives / Guidelines]

posted by ssussu – China, 2019-07-17 11:45 (430 d 03:20 ago) – Posting: # 20381
Views: 1,857

Dear guys,
We did a BE trial using a partial replicated design(TRR,RTR,RRT), but it was fail to demonstrate BE because the Cmax of one subject after administration of test drug was too much higher than reference drug, and when excluding the data of this subject, the results showed bioequivalent. But actually there were no reason to exclude the data from this subject.
And we conducted another BE trial, this time using full replicated design(TRTR,RTRT), and this time the result showed bioequivalent.
What I want to ask is, whether the second trial which showed bioeuquivalent would be accepted by agency. Any suggestions about this if we want to convince the agency to accept the successful one?


Complete thread:

 Admin contact
21,068 posts in 4,392 threads, 1,465 registered users;
online 17 (0 registered, 17 guests [including 10 identified bots]).
Forum time: Saturday 15:05 CEST (Europe/Vienna)

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz